Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-80038114 in advanced prostate cancer
NCT05441501Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of JNJ-80038114 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With AEs by Severity and 1 more. Started Nov 2022; status: completed.
02
Drugs
JNJ-80038114
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05441501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441501.